Explore how gaps in female inclusion in clinical research impact health outcomes and what organizations are doing about it.
Reflective Representation in Clinical Research and Data
November 5, 2026
1:00 PM – 2:00 PM
Reflective Representation in Clinical Research and Data
November 5, 2026
1:00 PM – 2:00 PM
The third webinar in AdvaMed’s 2026 Women’s Health webinar series will provide an in-depth discussion about how gaps in female inclusion in clinical research impact downstream health, healthcare delivery, and medical product innovation. Presenters will examine the consequences of underrepresentation in research, including an incomplete evidence base and disease-specific treatment guidelines that fall short, both of which can lead to problems like less impactful USPSTF recommendations and delayed diagnoses and treatment.
Presenters will then highlight their own success stories, sharing the initiatives and concrete steps their organizations have undertaken to improve recruitment and retention of female participants in clinical research. Along the way, missed opportunities and lessons learned will also be on the table. Finally, the discussion will turn to how improved clinical studies can drive more meaningful regulatory and coverage decisions — and what that means for the future of women’s health innovation.
Who Should Attend
This webinar is designed for:
- Women’s health start-ups and early-stage company leaders
- Founders, CEOs, and executive leaders
- Clinical Researchers, physicians
- Corporate venture and strategic investment teams
- Business development and innovation leaders
- Entrepreneurs and innovators developing women’s health technologies
- Medtech professionals interested in women’s health market trends
Panel
Roberta Bogaev Chapman MD, FACP, FACC, FHFSA, Vice President, Heart Recovery | Johnson & Johnson MedTech
Dr. Roberta Bogaev Chapman is a physician scientist and cardiovascular leader whose career has been dedicated to advancing therapies for patients with advanced heart failure and cardiogenic shock. She currently serves as Vice President of Heart Recovery at Johnson & Johnson MedTech, where she directs global clinical and translational research strategies focused on myocardial recovery, mechanical circulatory support, and escalation algorithms in acute and chronic heart failure.
Dr. Chapman earned her mechanical engineering degree from Virginia Tech and her medical degree from the University of Virginia where she completed her postgraduate training in internal medicine and cardiology with a subspecialty focus on advanced heart failure and transplant. Dr. Chapman has over two decades of leadership experience serving as the Medical Director of Heart Transplantation at Methodist Hospital in San Antonio and at Texas Heart Institute in Houston, Texas where she was faculty at Baylor College of Medicine and directed the heart failure fellowship training program.
Prior to joining Abiomed, Dr. Chapman served as Medical Director of the Advanced Heart Failure Program and Chief of Cardiology for Bon Secours Mercy Health in Virginia. She plays a pivotal role in designing and executing landmark clinical trials and translational programs that shape standards of care in acute decompensated and chronic heart failure, high-risk revascularization, and mechanical circulatory support. Her work emphasizes data-driven precision medicine, regulatory alignment, and patient-centric innovation. Dr. Chapman is a Fellow of the American College of Cardiology (FACC), the American College of Physicians (FACP) and the Heart Failure Society of America (FHFSA). She is widely respected for her commitment to mentorship, physician leadership development, and bridging clinical insight with MedTech strategy. Her professional purpose is rooted in integrity, authenticity, and service to others – advancing therapies that restore both heart function and human hope.
Oriana Popin-Zaghbi, CEO and Co-Founder, AOA Dx
Oriana Papin-Zoghbi is the CEO and co-founder of AOA Dx and a visionary leader in women’s health innovation and diagnostics. Under her leadership, AOA Dx has raised over $30 million to advance a first-in-class diagnostic platform aimed at transforming ovarian cancer detection. She has built and scaled a high-performing, mission-driven team, guiding the company through product and clinical development, regulatory strategy, and rapid organizational growth.
Recognized in Inc.’s Top 100 Female Founders for her groundbreaking work in ovarian cancer diagnostics, Oriana is a strong advocate for closing critical gaps in women’s health. She brings deep global experience launching and commercializing diagnostics—from HPV screening programs in East Africa to innovations in oncology, maternal-fetal medicine, and infectious diseases. Oriana holds a degree in Economics and International Relations from Boston University and brings a global, equity-focused perspective to advancing women’s health worldwide.
Hear From Us
Sign up to receive emails highlighting our upcoming events, early registration savings, and engagement opportunities for the medical technology community.